NIH CRADAs as of March 11, 1997, By Title

  1. 50MG Each of BB94 (Batimastat) and BB2516 (Marimastat) - NIDR
  2. A double blind, randomized, placebo-controlled clinical trial of LHRH analog in pubertal patients with isolated GH deficiency treated with GH. - NICHD
  3. Abrogation of Cytotocity, Stimulation of Bone Marrow and Inhibition of Metastasis by Lipid-Complexed Swainsonine - NIEHS
  4. Adeno-HIV Recombinants - NCI
  5. Adenosine Receptor Agonists in Cerebral Ischemia - NIDDK
  6. Adenoviral Gene Transfer for the Treatment of Cardiovascular Diseases - NHLBI
  7. Adoptive Transfer of Human T Cell Clones for Treatment of Immunologicially Mediated and Infectious Diseases - NIAID
  8. Age Related Eye Disease Study - NEI
  9. Agracetus, Inc., to provide ACCELL gene gun instrument and relevant know-how. - NIAID
  10. Amendment to Hepatitis X Virus
  11. Amgen's Proprietary Glial Cell Line Derived Neurotrophic Factor (GDNF) - NICHD
  12. An Aliquot of GS 2888 - NCI
  13. Antagonist of HIV-1, RSV and HPIV-3 Viral Membrane Fusion - NIDDK
  14. Anti-Tumor Activity of Integrin Inhibitors Against Squamous Cell Neoplasms that Affect Human Communication - NIDCD
  15. Antibodies raised in chickens against somotostatin receptor subtypes 1,2,3,4, and 5. - NINDS
  16. Antigen-Specific T Cell Death for the Treatment of Autoimmune Disorders and Graft Rejection - NIAID
  17. Antiserum Directed Towards the B4B Protein - NIEHS
  18. Assessment of Borrelia burgdorferi Transfer in Binding Factors as Protective Immunogens Against Lymo Disease - NIAID NIAID
  19. Assessment of the Ability of a Human Fetal Astrocyte Cell Line to Reverse the Extrapyramidal Signs in a Primate Model of Parkinson's Disease - NINDS
  20. Assessment of transduction efficiency using a proprietary vector on elutriated, FACS sorted LIN-CD34+ and LIN-CD34+CD38 Cells - NHGRI
  21. Avitech Diagnostics, Inc., will provide 50,000 units of the proprietary compound T4 Endonuclease VII - NCI
  22. BB 2116 and BB 2516 - NIAID
  23. BB 10010 - NIAID
  24. BMP2 protein, BMP4 protein, and BMP7 p rotein - NINDS
  25. Breeding Pairs of HLA-A2/Dd transgenic mice epressing the Alpha-1 and Alpha-2 domains of HLA-A2.1 with the Alpha-3 domain of H-2Dd. - NCI
  26. Carcinogenic Mechanisms of Middle Distillate in Tumor Model System - NCI
  27. CD28-B7 Costimulation in Immune Dysregulation - NCI
  28. Cells, serum, plasma, tissue and/or other mutually agreeable material - NIA
  29. Certain chemicals as described by PI or Retinoid Group (SRI) - NIEHS
  30. Characterization of the NCI Cancer Screening Panel Regarding RTK/TK and Phosphatase Expression Status and Profiling of NCI and Sugen Lead Structures - NCI
  31. Characterization, Isolation, and Expression of the Gene Coding for the Anti-Trypansosomal Factor, ATF-II, from Pseudomonas Fluorescens - NIAID
  32. Chemical libraries - NIAID
  33. Cholera Toxin as an Adjuvant for Targeting Protective Mucosal Immunity against Species Common T and B-Cell Epitopes of the Major Outer Membrane Protein of Chlamydia Trachomatis - NIAID
  34. Clinical Development of 9-Aminocamptothecin - NCI
  35. Clinical Development of SU-101 - NCI
  36. Clinical Development of Suramin - NCI
  37. Clinical Development of Taxol: Amendment
  38. Clinical Development of Tomudex TM - NCI
  39. Cold Adapted Influenza Vaccine - NIAID NIAID
  40. Collaborative Development of a Core Laboratory for Cell Processing and Gene Therapy - CC
  41. Compounds with the Ability to Prevent Fas-Induced Apoptosis - NCI
  42. Continued Investigations of Oncanase, a Novel Anti-Cancer Agent
  43. Corixa Corporation will provide LEIF protein and TB antigens
  44. CT6F Recombinant Protein - NIA
  45. CX16 (Pharmaceutical Grade) - NINDS
  46. Cyclic Nucleotide Phosphodiesterase (PDE) Subtypes in Chronic Pulmonary Inflammatory Diseases - NHLBI
  47. Detection of BRCA1 Mutations by DNA Chip Hybridization - NHGRI
  48. Development and Commercialization of Parvovirus B19 Diagnostic Tests and Vaccine and Exploration of the Utility of the Parvovirus B19 Non Structural Protein - NHLBI
  49. Development of a Clinical Pathology Laser Capture Microdissection System for Routine Clinical Use - NCI NCRR
  50. Development of a Fully Automated Karyotyping System Based on Co-Hybridization of Cy-5 Labeled Chromosome Specific Repeat Probes - NHGRI
  51. Development of a Hybridization Based Multicolor Karyotype of the Human Chromosome Complement Using Spectral Bio-Imaging - NHGRI
  52. Development of a Live Orally Administered Rhesus Rotavirus Vaccine - NIAID
  53. Development of a Live, Attenuated Cold-Adapted Influenza Vaccine - NIAID
  54. Development of a Proteinase Inhibitor as a Potential AIDS Therapeutic - NCI
  55. Development of a Purification Process Using Different Types of Expanded Bed Resins - NIDDK
  56. Development of a Retrovirus Ex Vivo Gene Therapy System for Ed Vivo Transduction of Hematopoietic Progenitors/Stem Cells to Provide Correction for Patients with Chronic Granulomatous Disease (CGD) - NIAID
  57. Development of a Safe and Effective Live Attenuated Respiratory Syncytial Virus Vaccine - NIAID
  58. Development of a Safe and Effective Treatment for Restenosis and Atherosclerosis - NHLBI
  59. Development of a Safe Synthetic Peptide Based Vaccine for Protection from Infection by the Pathogenic Serovars of Chlamydia - NIAID
  60. Development of a Sputum Based Early Lung Cancer Detection System - NCI
  61. Development of Adenovirus-Based Cancer Vaccines - NCI
  62. Development of an Electronic Procurement System for Commodity Indentification, Product & Service Acquisition and Budget Tracking - NCI
  63. Development of an Integrated Microscope System for Automated Digital Image Acquisition for FISH-Applications - NHGRI
  64. Development of Anti-Cancer Vaccines Using the Accell Gene Delivery System (Gene Gun) - NCI
  65. Development of Antibodies Against the Human CaR for Diagnosis and Localization of Parathyroid Tumors in Patients with Hyperparathyroidism (HPT) - NIDDK
  66. Development of Buprenorphine Products for the Treatment of Opioid Dependence - NIDA
  67. Development of Cell Lines Permissive for Efficient Amplification of Adenoviruses with Deletions and./or Substitutions of Viral Genes Essential for Viral Replication - NHGRI
  68. Development of Expression Vectors to Produce Human Glucocerebrosidase (hGC) in the Milk of Transgenic Animals and Purfication of the Protein - NIMH
  69. Development of Gibbon Ape Leukemia Virus-based Kat Retroviral Vectors for Human Gene Therapy - NIMH
  70. Development of Hepatitis A Vaccine - NIAID
  71. Development of Hepatitis C - NIAID
  72. Development of LMB-7 Immunotoxin - NCI
  73. Development of PMZ-1 - NCI
  74. Development of PMZ-1 - NCI
  75. Development of Poxvirus Based Cancer Vaccine - NCI
  76. Development of Radiochemically and Radiopharmaceutically Elegant Synthesis of FDG - CC
  77. Development of Recombinant Cancer Vaccines - NCI
  78. Development of Screening Tests for Carcinogenic or Anticarcinogenic Compounds - NCI
  79. Development of Synthetic Peptide Inhibitors of Monocyte Chemotactic Protein-1 and Rellated C-C Chemokines - NCI
  80. Development of the Cold-Adapted PIV3 Virus - NIAID
  81. Development of Vectored Vaccines and Therapeutics for the Prevention and Treatment of AIDS - NCI
  82. Diabetes Prevention Program (DPP-2) - NIDDK
  83. Drug Development Program for the Treatment of Mycobacterial Diseases - NIAID
  84. Drug Interactions with Insulin in Regulating Glucose Transport
  85. E4 Hybridoma Cells, Reactive with Prostate Antigen - NCI
  86. Endothelial Selectin-Directed Monoclonal Antibodies to Reduce Septic Shock in Rats Undergoing Intravenous or Intrabronchial Challenge with E. Coli: Variation of Effect by Site and Severity of Infection - CC
  87. Enhanced Bacteriophage Anti-Bacterial Therapy - NIMH
  88. Enzymatic Mutation Detection TM (EMDTM) kits for screening DNA samples outlined in Appendix A - NICHD
  89. Enzyme and Gene Therapy of Fabry Disease
  90. Enzyme Replacement Therapy for Fabry Disease - NINDS
  91. Evaluation of Acellular Pertussis Vaccine - NIAID
  92. Evaluation of Beta-alethine and Related Compounds in the Regulation of Immune and Hematopoetic Responses in Transplanation and Cancer Immune Therapy - NCI
  93. Evaluation of HSV-tk Mutants - NHGRI
  94. Evaluation of Mode of /Action and Therapeutic Potential of a Novel Aminosterol in the Treatment of Human Immunodeficiency Virus (HIV) Disease - NIAID
  95. FII276 and 297 - NCI
  96. Florescent-Based Genotyping Technology for Complex Diseases - NHGRI
  97. Flt3 Ligand, PSGL-1 and Murine Skin Dendritic Cells - NCI
  98. Functional Analysis of CD8+ Lymphocytes RedirectedAgainst TAG-72 Positive and/or CEA Positive Tumors by MHC-Unrestricted, Chimeric Antigen Receptors - NCI
  99. GEMMSTAR, A two-Gigaflop Computer for Molecular Simulation - DCRT
  100. Gene Finding for Aging and Cancer Disorders - NIEHS
  101. Gene Isolation and Capture Through Transformation Associated Recombination (TAR) - NIEHS
  102. Gene Therapy for AIDS Using Retroviral Mediated Gene Transfer to Deliver HIV-1 Antisense TAR and Transdominant REV Proteins - NHGRI
  103. Gene Therapy for AIDS Using Retroviral Mediated Gene Transfer to Deliver HIV-1 Antisense TAR and Transdominant REV Proteins - NHGRI
  104. Gene Therapy for CNS Tumors - NINDS
  105. Gene Therapy for Hemophilia Using Second Generation Recombinant Adenoviral Vectors - NHGRI
  106. Gene Therapy of Gaucher's Disease - NINDS NHLBI
  107. Gene Transfer of Universal T-Cell Receptor - NHLBI
  108. Generation of Immunotoxins Targeted to the CD 22 Antigen for the Treatment of B Cell Leukemias and Lymphomas - NCI
  109. Genetic Determinants of Non-Insulin-Dependent Diabetes Mellitus - NIDDK
  110. Genetic Markers and Candidate Genes From Microdissected Human Chromosomes - NIMH
  111. Genetic Studies of Bipolar Affective Disorders and Related Diseases - NIMH
  112. GM-CSF cDNA - NCI
  113. Growth of Varicella-Zoster Virus (VZV) Mutants in the SCID-HU Mouse - NIAID
  114. HIV Integrase Inhibitors: Determination of Binding Sites and Design of New Inhibitors - NCI NIDDK
  115. Hu CD30 Ligand Monoclonals + appropriate control antibodies - NIAID
  116. Humatrope in Non-Growth Hormone Deficient Children with Short-Stature - NICHD
  117. Identification and characterization of Selective Cocaine Antagonists - NIDA
  118. Identification of Immune Response Modulating Viral Proteins - NIAID
  119. Identification of Neutophil and Monocyte Chemokines Induced by Interleukin-8 and Monocyte Chemotactic Protein-1 - NCI
  120. Identifying Genes that Control IgE Production in the Mouse - NIAID
  121. IL-12 Gene Expressin Vector (pWRG3169) Which Encodes both Subunits of IL-12 (to be supplied to requestor by Agracetus) - NIAID
  122. IL-12 p35 and p40 Knockout Mice - NCI
  123. IL3 Protein, IL9 Protein, GMCSF Protein, MCSF Protein - NHLBI
  124. Immunotoxins for Tumor Therapy - NINDS
  125. Improved Adeno-Associated Viral Vectors and Their Application to Gene Therapy of Hemophilia A and B - NHLBI
  126. In Vitro and In Vivo Tests of Proprietary Compounds on Hematopoietic Cells - NCI
  127. Inhibition of Various Amyloid Accumulations (Including Scrapie-Associated PRP) Using Molecules Resembling Elements of Gag Structure - NIAID
  128. Isolation and Characterization of Ligands for the Insulin Receptor and Related Receptor (IRR) - NIDDK
  129. JAK3 Structure and Function Analysis: Molecular Basis fo JAK3 Interactions with IL-2R-GAMMA - NIAMS
  130. KOH(ICE) 164BBC Mice, Homozgous; KOW(ICE) 164BBC Mice, Wildtype - NIAID
  131. LieF and "Beads as Vaccine Carriers" - NCI
  132. Lipolysis in Adipocytes: Mechanism and Inhibitors
  133. MDR Gene Expression in Hematopoietic Stem Cells - NCI NCI
  134. Mechanism of Action of a Synthetic Peptide Which Inhibits Endocytocsis - NIDDK
  135. Mediation of Immunogenic Response to Recxcombinant Immunotixins Using Antibodies to CD40-Ligand - NCI
  136. Miniaturization of Polymerase Chain Reaction Device for Holding Small Liquid Samples - NIAID
  137. Modulation of MHC Antigen Expression in AutoimmuneDisease and Transplantation - NIDDK
  138. Monoclonal antibodies 36A1, 58B1, and other monoclonal antibodies isolated by the Weizmann Institute, that interact with cholesterol - NHLBI
  139. Monoclonal Antibody Against NCAM - NINDS
  140. mscvneoEB, mscvhph, mscpac Retroviral vectors - NINDS
  141. Multidrug Resistance Gene Clinical Trial Studies - NCI NCI
  142. Murine IL12 Protein - NIAID
  143. Murine, IL12 Protein - NIAID
  144. Novel Molecular Approaches to Tissue Repair - NIDR
  145. Novel Therapeutic Vaccines for B-Cell Lymphomas - NCI
  146. NSC 691766D (V18, 563) - NCI
  147. Onconase Gene Fusions - NINDS
  148. Osteogenic Protein-1/Bone Morphogenic Proteins in Renal Development and Renal Disease - NIDDK
  149. Phase II, TF-CRM107 (HN-66000) Trial in Patients with Glioblastoma and Astrocytoma - NINDS
  150. Phenyl Derivatives as Cancer Therapeutic Agents - NCI
  151. pMGS 3 and pMGS transfer plasids - NIAID
  152. PMPA for Evaluation in SIV Infected Monkeys - NCI
  153. Potassium Ion Channel Probes - NCI
  154. Preclinical Evaluation of Gene Therapy w/Replication Devidient Recombinant Adenovirus to Prevent and Treat Restenosis After Angioplasty and to Induce Angiogenesis to Restore Blood Supply to the Ischemic Myocardium - NIA
  155. Production of Human Metabolic Enzymes in Transfected Plants
  156. Production of Live Attenuated RSV and PIV Vaccine Viruses from cDNA - NIAID
  157. Production of Recombinant Cartilage-Derived Morphogenetic Proteins and Evaluation of their Biological Functions - NIDR
  158. Production, Clinical and Functional Evaluation, and Commercial Development of Diagnostic Antibodies to the KAI1 Metastasis Suppressor Gene product - NIEHS
  159. Protease Nexin I (PN1) - NICHD
  160. Protein Separation with Polymer Phase Systems by Affinity Countercurrent Chromatography - NHLBI
  161. Provide a gene construct encoding an anti-TAC antibody 6to PBL - NCI
  162. Purified Recombinant Human MBP21-5 Protein - NINDS
  163. Quantitation and Pharmacokinetic Characterization of AG337 - NCI
  164. Quantitative Analysis of Gene Expression by Micro-Arrays - NHGRI
  165. Receptor bodies for Eph-related tyrosine kinase receptors - NICHD
  166. Recombinant Human Glucocerebrosidase for Enzyme Replacement in Gaucher's Disease - NIMH
  167. Recombinant human Glial Growth F\actor 2 (rhGGF2) - NINDS
  168. Recombinant Rat Stem Cell Factor - NHGRI
  169. Regulation of Schistosoma mansoni egg granuloma formation by soluble P selectin and IL-13 receptor antagonist - NIAID
  170. Research for the Development of the Journal of the National Center Institute as a Dynamic Knowledge Center - NCI
  171. Research material as determined - NIAID
  172. Retroviral Mediated Gene Transfer of the Fanconi Anemia Complementation Group C Gene to Hematopoietic Progenitors of Group C Patients - NHLBI
  173. Role of AG2034 as a Selective Inhibitor of Glycinamide Ribonucleotide Transformylase in Human Epithelial Cancer Cell Lines - NCI
  174. Role of Anti-Human Fas M3, MCD40, MCD40-Ligand, and Flt 3-Ligand in Developing Recombinant Anti-Cancer Vaccines - NCI
  175. Role of Certain Signal Transduction Pathways in Malignant Cell Growth and in Cell Death - NCI
  176. SB 203580 and SK & F 106978 - NIA
  177. Scientific and Commercial Development of Diagnostic and/or Therapeutic Agents for Hyperpigmentary Lesions - NCI
  178. Serum Proteins Patterns - NIMH
  179. Studies on the Clinical and Laboratory Effects of Inhibition of TNF-Alpha in Patients with HIV Infection - NIAID
  180. Studies with Parathyroid Gland Inhibitors - NIDDK
  181. Study of Encapsulated Engineered Cells in Parkinsonian Monkeys - NINDS
  182. Study of Lipid DODAC/DOPE LUV
  183. Study of LY303366 in the Treatment of Primary Pulmonary Aspergillosis in Persistently Granlocytopenic Rabbits - NCI
  184. Technology which entails the use of directed motion gene transfer to cells for the purpose of cell transduction, also known as "Gene Loader" - NHGRI
  185. Testing and Development of Specific Monoclonal Antibodies as Immunotoxins
  186. TGB-Beta2 - NCI
  187. The Compounds RO62-0852/000 and RO 61-8048/000 Inhibitors of Kynu---Hydroxylase - NIMH
  188. The Development of a Safe and Effective Vaccine Against Hepatitis E Virus (HEV) - NIAID
  189. The Development of Adeno-Associated Vectors for Gene Transduction - NHLBI
  190. The Role of Flt-3 Ligand and Murine CD40-Ligand in the Function of Recombinant Anti-Cancer Vaccines - NCI
  191. The Role of IL-15 Protein and cDNA in the Function of Recombinant Anti-cancer Vaccines - NCI
  192. The role of Fas-Fc in the apoptosis of anti-tumor T lymphocytes - NCI
  193. The role of T7/T7 in the design and function of recombinant anti-cancer vaccines - NCI
  194. The Use of GS-G6, and G8 Dendrimers as an Intravascular Contrast Agent for Cardiac Imaging - NCI NHLBI
  195. Therapeutic and Diagnostic Research Using a Novel Carries System for the Delivery of Compounds to the Brain - NIMH
  196. Therapy of Cancers Expressing erbB2 Oncogene - NCI
  197. TNFR-DKO - NIAID
  198. To develop the ability of retinoids supplied by SRI to arrest cell growth and induce differentiation in an in vitro retinoid sensitive neuroblastoma cell line. - NCI
  199. Trapping and Characterization of Exons from a Region Implicated in Prostate Cancer - NHGRI
  200. Treatment of Chronic Progressive Vascular Disease - NIDDK
  201. Treatment of Dysphagia Using Laryngeal Stimulation Device - NIDCD
  202. Treatment of Ocular Inflammatory Disease - NEI
  203. Use of Monoclonal Antibodies and Developmentof Novel Recombinant Immunoglobuling Forms for Radioimmunoguided Surgery of Cancer
  204. Use of NONOate Compounds in the Development of Treatments for Vascular and Cardiovascular Restenoisis - NCI
  205. Use of Oestrone-3-Sulphamate (EMATE) in the Study of the Role of Cholesterol Sulfate in Protein Kinase C Signal Transduction - NCI
  206. Viral Vectors for Gene Therapy - NHGRI
  207. Wildtype adenovirus and mutants (UPENN CTT 928) that may be able to cause monocytes to differentiate into dendritic cells. - NCI
  208. Yeast-derived Soluble Trimeric /CD40-Ligand (200-400) and Anti-Leucine Zipper Antobody M48 (200-400) - NIDR NIAID